Debating the Follow-up Duration and Relevance of Determination Data in Myeloma Treatment

While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years. Novel immunotherapies, including CAR-T therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), continue to transform the myeloma treatment landscape and provide patients with more hope. At the 2022 EHA Annual Meeting, there were several exciting updates presented, with a large focus being placed on clinical trials and novel immunotherapies.

In this exclusive podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discuss key advances in myeloma treatment from this year’s EHA meeting, drawing focus on the DETERMINATION trial (NCT01208662) and the promise of novel immunotherapies.

The post Myeloma treatment updates from EHA 2022 appeared first on VJHemOnc.